(本文来自第一财经) 盟科药业跌超10%，博瑞医药、百诚医药跌超7%，悦康药业、康辰药业、苑东生物、富祥药业等跌幅 居前。 ...

Group 1 - Shengke Communication's shareholding by the National Integrated Circuit Industry Investment Fund has decreased from 19.6% to 15% after a total reduction of 18.8569 million shares [1] - Guoxin Technology plans to reduce its shares by up to 4.5% through various trading methods between September 30, 2025, and December 29, 2025 [1][2] - Jingzhida has delivered its first high-speed testing machine to a key domestic customer, aimed at semiconductor memory testing [4][5] Group 2 - Nanxin Pharmaceutical's shareholder plans to reduce shares by up to 3%, totaling 823.2 million shares, due to funding needs [6] - *ST Taihe's shareholder intends to reduce shares by up to 3% for operational management needs [7] - Xincheng Technology's shareholders and directors plan to reduce shares by up to 2.03% due to personal funding needs [8] Group 3 - Huati Technology is planning to acquire shares of Huayi Microelectronics, leading to a stock suspension due to uncertainties [9] - Ruima Precision's subsidiary has received a project notification with a total lifecycle sales estimate of approximately 5.56 billion yuan [10] - Guoguang Electric's shareholders plan to reduce shares by up to 3.85% through various trading methods [10] Group 4 - Cangge Mining's shareholder plans to reduce shares by up to 0.6% due to funding needs [11] - Jujiao Co., Ltd. intends to reduce shares by up to 3% due to personal funding arrangements [12] - Maqu'er plans to reduce shares by up to 2% due to funding needs [13] Group 5 - Caesar Travel's subsidiary intends to acquire 100% equity of Qingdao Hansa for 16 million yuan [14] - Xinde New Materials' shareholders plan to reduce shares by up to 3% through various trading methods [15] - Huadong Heavy Machinery's shareholders plan to reduce shares by up to 1.5% [16] Group 6 - Zhejiang Zhongcheng's shareholder plans to reduce shares by up to 3% due to personal funding needs [17] - Huaxi Securities' shareholder plans to reduce shares by up to 1% due to liquidity needs [18] - Ameng Pharmaceutical's major shareholder opposes the introduction of a strategic investor due to concerns over financial strength and compliance [19] Group 7 - *ST Rindong plans to invest 100 million yuan in Jiangyuan Technology, with a post-investment shareholding of 4.14% [20][21] - International Industry plans to issue shares to its controlling shareholder to raise no more than 662 million yuan for working capital [22][23]

Market Overview - On September 25, A-shares opened slightly lower, with the three major indices collectively in the red [1] - The Shanghai Composite Index decreased by 0.06%, the Shenzhen Component Index fell by 0.30%, and the ChiNext Index dropped by 0.45% [2] Sector Performance - The non-ferrous metals, media, electric equipment, and pharmaceutical sectors showed notable gains, with the nuclear fusion and copper industries being particularly active [2][4] - The nuclear fusion sector rose by 2.67%, while the copper industry increased by 2.63% [4] Copper Industry Insights - The copper industry index led the gains, with companies like Jingyi Co., Northern Copper, and Luoyang Molybdenum hitting the daily limit [8] - A recent landslide at Freeport McMoRan's Grasberg mine in Indonesia has raised global copper prices and sparked supply chain concerns, as this mine accounts for approximately 3% of global copper supply [9][10] Nuclear Fusion Sector Developments - The nuclear fusion concept stocks collectively surged, with companies like Hezhong Intelligent and Farsen hitting the daily limit, and others like Shanghai Electric and Baoli Electric also seeing significant increases [10][11] - China Fusion Energy Co., known as the "national team" for controllable nuclear fusion, is focusing on overall design, technology verification, and digital R&D [14] Company Specifics - On September 25, the stock of Upwind New Materials surged to a limit of 20%, reaching a price of 132.1 CNY per share, with a total market value of 53.3 billion CNY [15][16] - The company recently completed a share transfer, changing its controlling shareholder to Zhiyuan Hengyue, with plans for a tender offer to acquire an additional 37% of shares at a price of 7.78 CNY per share [18]

Core Viewpoint - The capital increase plan by Amgen Pharmaceuticals (688373.SH) aims to raise 1.033 billion yuan by issuing 164 million shares at 6.3 yuan each, which will not only meet funding needs but also change the equity structure, making Nanjing Haiqing Pharmaceuticals the controlling shareholder with a 20% stake [1][2]. Group 1: Capital Increase and Shareholder Dynamics - The capital increase will address the company's funding requirements and alter the shareholder structure, with Haiqing Pharmaceuticals becoming the new controlling entity [1]. - The opposition from board member Zhao Yachao and Genie Pharma, the largest external shareholder, indicates significant internal conflicts regarding the capital increase [2][3]. - The actual control of Genie Pharma lies with Yang Zhi, who is also linked to Baio Weida, suggesting a complex web of interests that may influence the decision-making process [2][3]. Group 2: Strategic Implications of the Capital Injection - The capital injection is expected to cover operational cash flow needs for over two years, directly supporting the development and commercialization of key drug candidates like MRX-4, MRX-5, and MRX-8 [4][7]. - Amgen's core competitiveness is rooted in its well-structured pipeline, focusing on innovative antibiotics for drug-resistant infections, with a strong emphasis on research and international clinical trials [5][6]. - The partnership with Haiqing Pharmaceuticals is anticipated to enhance Amgen's operational capabilities, transitioning the company from a research-driven model to a more integrated research-production-sales approach [5][6][9]. Group 3: Future Growth and Market Position - The collaboration is expected to yield significant commercial benefits, with projected sales revenues of 260 million, 388 million, and 600 million yuan from 2026 to 2028, indicating a doubling of sales over three years [6][7]. - The integration of Haiqing's resources is likely to optimize production processes and reduce costs, enhancing overall efficiency [6][7]. - The capital increase and strategic partnership mark a pivotal moment for Amgen, potentially leading to a shift in valuation from pipeline-based to performance-based metrics [7][8][10].

盟科药业第一大股东强势反击了。 据盟科药业9月24日晚发布公告，公司第一大股东Genie Pharma对公司2025年第二次临时股东大会所审议的包括定增等在内的多项议案均投反对票，并公 开征集投票权反对部分议案。 Genie Pharma还提请在股东大会增加关于罢免ZHENGYU YUAN（袁征宇）等3人董事职务的议案，以及选举杨宗凡等3人为董事的议案。其中， ZHENGYU YUAN（袁征宇）目前是盟科药业董事长、总经理、法定代表人。 此前，盟科药业9月22日晚发布公告称，拟向海鲸药业发行股票募资不超过10.33亿元；海鲸药业拟认购公司1.64亿股，发行完成后将持有盟科药业20%股 份，成为其控股股东，自然人张现涛将成为实际控制人。 【导读】盟科药业第一大股东提请罢免公司董事长等3名董事，并公开征集投票权反对部分议案 自2022年8月上市至今，盟科药业一直是无控股股东和实际控制人，其前两大单一股东分别为Genie Pharma和盟科香港，两者持股比例相差很小，分别为 10.92%、10.79%。 9月23日，盟科药业20%涨停。9月24日，盟科药业股价以9.67元/股报收，微跌0.41%。9月25日开盘，盟 ...

【导读】盟科药业第一大股东提请罢免公司董事长等 3 名董事，并公开征集投票权 反对部分议案 中国基金报记者 卢鸰 盟科药业第一大股东强势反击了。 据盟科药业 9 月 24 日晚发布公告，公司第一大股东 Genie Pharma 对公司 2025 年第二次临时股东大会所审议的包括定增等在内的 多项议案均投反对票，并公开征集投票权反对部分议案。 Genie Pharma 还提请在股东大会增加关于罢免 ZHENGYU YUAN （袁征宇）等 3 人董事职务的议案，以及选举杨宗凡等 3 人为董事 的议案。其中， ZHENGYU YUAN （袁征宇）目前是盟科药业董事长、总经理、法定代表人。 此前，盟科药业 9 月 22 日晚发布公告称，拟向海鲸药业发行股票募资不超过 10.33 亿元；海鲸药业拟认购公司 1.64 亿股，发行完成 后将持有盟科药业 20% 股份，成为其控股股东，自然人张现涛将成为实际控制人。 盟科药业 9 月 24 日晚发布公告称，第一大股东 Genie Pharma 认为， ZHENGYU YUAN （袁征宇）在任职期间未能勤勉履责，未进 行及时调查、核查，损害了公司及其他股东的合法权益。具体表现如 ...

中国基金报记者 卢鸰 盟科药业第一大股东强势反击了。 据盟科药业9月24日晚发布公告，公司第一大股东Genie Pharma对公司2025年第二次临时股东大会所审议的包括定增等在内的多项议案均投反对票，并公 开征集投票权反对部分议案。 Genie Pharma还提请在股东大会增加关于罢免ZHENGYU YUAN（袁征宇）等3人董事职务的议案，以及选举杨宗凡等3人为董事的议案。其中， ZHENGYUYUAN（袁征宇）目前是盟科药业董事长、总经理、法定代表人。 此前，盟科药业9月22日晚发布公告称，拟向海鲸药业发行股票募资不超过10.33亿元；海鲸药业拟认购公司1.64亿股，发行完成后将持有盟科药业20%股 份，成为其控股股东，自然人张现涛将成为实际控制人。 自2022年8月上市至今，盟科药业一直是无控股股东和实际控制人，其前两大单一股东分别为Genie Pharma和盟科香港，两者持股比例相差很小，分别为 10.92%、10.79%。 9月23日，盟科药业20%涨停。9月24日，盟科药业股价以9.67元/股报收，微跌0.41%。 9月25日开盘，盟科药业股价跳水，截至发稿跌幅超6%。 【导读】盟科药业第一大股东 ...

中经记者 晏国文 卢志坤 北京报道 2025年上半年，盟科药业营业收入为6696.98万元，归属净利润为-1.39亿元。 （盟科药业公司外景 官网/图） 9月23日，科创板医药上市公司盟科药业（688373.SH）公布，拟向海鲸药业发行股票，募集资金不超 过10.33亿元。不过，盟科药业一名董事赵雅超投了反对票，并提出了三点反对意见。 盟科药业上述股票发行预案显示，除赵雅超外，公司及董事会全体成员保证内容真实、准确、完整。 《中国经营报》记者注意到，针对盟科药业2025年半年报，赵雅超也表示无法保证真实性、准确性和完 整性。赵雅超是2024年8月起担任盟科药业董事的，未持有盟科药业股份。 9月24日，盟科药业的第一大股东Genie Pharma（持股10.92%）也表示，将征集投票权对盟科药业股票 发行议案投反对票。 董事接连对公司定期报告和重大事项表示无法保证真实性、准确性和完整性以及股东也投出反对票，这 是否反映出盟科药业管理团队及股东之间存在重大分歧和矛盾呢？ 针对相关问题，盟科药业方面未对记者采访做出回应。 长期亏损 盟科药业于2022年8月在科创板上市，但长期亏损，而且存在亏损加剧的趋势。2022年 ...

北京商报讯（记者 丁宁）9月25日，盟科药业（688373）盘中股价大跌，一度跌逾7%。截至北京商报 记者发稿，盟科药业报8.95元/股，跌幅为7.45%。 消息面上，盟科药业发布公告称，股东Genie Pharma作为征集人，就公司拟于10月9日召开的2025年第 二次临时股东大会审议的有关议案向公司全体股东征集投票权。公告显示，Genie Pharma对盟科药业 2025年第二次临时股东大会所审议议案除议案9外均投反对票，包括《关于公司向特定对象发行股票方 案的议案》等。截至征集公告披露日，征集人Genie Pharma合计持有公司股份数量7157.28万股，均为有 表决权股份，占公司股份总数的10.92%，为公司第一大股东。 ...

Genie Pharma表示，结合目前银行并购贷投放比例，海鲸药业若以债务性融资参与本次定增，其资产负 债率将大幅提升，考虑到其智能工厂项目仅为1期投入，若2期进入建设及资本投入期，其资金面将严重 吃紧，其债务性融资可能影响上市公司控制权稳定性。此外，本次融资及后续股权结构可能导致销售渠 道、销售人员混同，上市公司独立性受损。 值得一提的是，根据公告，公司于9月24日收到公司股东Genie Pharma出具的《关于提请上海盟科药业 股份有限公司2025年第二次临时股东大会增加临时提案的函》，其提请在本次股东大会增加以下临时提 案并提交本次股东大会审议。包括关于罢免ZHENGYU YUAN（袁征宇）公司第二届董事会董事职务的 议案，关于选举杨宗凡为公司第二届董事会董事的议案等。 北京商报讯（记者 丁宁）9月25日，盟科药业（688373）发布公告称，股东Genie Pharma作为征集人， 就公司拟于10月9日召开的2025年第二次临时股东大会审议的有关议案向公司全体股东征集投票权。 公告显示，Genie Pharma对盟科药业2025年第二次临时股东大会所审议议案除议案9外均投反对票，包 括《关于公司向特定对 ...